The effect was drastically reduced for 125I-labelled internalizing anti-EGFR mAbs and the corresponding unlabelled mAbs (77 days vs 76 days, respectively), however, this lower effectiveness could be explained by the catabolism of the internalised 125I-labelled mAbs with export of released 125I from the tumour cells (Santoro et al. 2009). This evidence concerns the gene EGFR and neoplasm.